What Siegall Has Just Discovered
Clay Siegall is one of the most active researchers regarding cancer. He has personally involved himself in decades of research examining cancer and how patients respond to various treatments. This research he did in the 90s eventually led him to the creation of Seattle Genetics. At Seattle Genetics, Clay Siegall has patented various products and brought them to market. Seattle Genetics is so successful Siegall is now talking to various pharmaceutical companies such as Pfizer which are interested in bring his products into the market.
The Magic At Work At Seattle Genetics
The major accomplishment of Clay Siegall at Seattle Genetics is the antibody-drug conjugate. This unique treatment option fights cancer by using antibodies to deliver drugs in an attempt to prevent the body from regarding the drugs as foreign to the body. The treatment method offers an advantage because it prevents many of the side effects often observed in cancer therapy. Cancer therapy as it stands today is woefully unprepared to help the patients in need of it. They may experience hair loss, organ failure, and other undesirable side effects on their road to recovery. These breakthroughs are a step in the right direction to eliminate that altogether.
Where It All Goes From Here
Seattle Genetics was able to generate more than $500 million in revenue from investors the last time the firm decided to seek out investors. Clearly, there is a strong interest in Seattle Genetics and there are clearly many interested in the firm’s potential. Clay Siegall has already given the world an amazing breakthrough in oncology, but he is far from finished with his studies. He wants to do so much more with his work.
About Clay Siegall
Clay Siegall is a cancer researcher with a strong focus on finding safer ways to treat cancer. He has worked with various institutions over the course of the years in order to better understand how cancer develops and how to treat it. He has used this research to create Seattle Genetics and the center’s key breakthroughs.